142 related articles for article (PubMed ID: 38662396)
1. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.
Montagna G; Mrdutt MM; Sun SX; Hlavin C; Diego EJ; Wong SM; Barrio AV; van den Bruele AB; Cabioglu N; Sevilimedu V; Rosenberger LH; Hwang ES; Ingham A; Papassotiropoulos B; Nguyen-Sträuli BD; Kurzeder C; Aybar DD; Vorburger D; Matlac DM; Ostapenko E; Riedel F; Fitzal F; Meani F; Fick F; Sagasser J; Heil J; Karanlik H; Dedes KJ; Romics L; Banys-Paluchowski M; Muslumanoglu M; Perez MDRC; Díaz MC; Heidinger M; Fehr MK; Reinisch M; Tukenmez M; Maggi N; Rocco N; Ditsch N; Gentilini OD; Paulinelli RR; Zarhi SS; Kuemmel S; Bruzas S; di Lascio S; Parissenti TK; Hoskin TL; Güth U; Ovalle V; Tausch C; Kuerer HM; Caudle AS; Boileau JF; Boughey JC; Kühn T; Morrow M; Weber WP
JAMA Oncol; 2024 Apr; ():. PubMed ID: 38662396
[TBL] [Abstract][Full Text] [Related]
2. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
[TBL] [Abstract][Full Text] [Related]
3. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.
Gentilini OD; Botteri E; Sangalli C; Galimberti V; Porpiglia M; Agresti R; Luini A; Viale G; Cassano E; Peradze N; Toesca A; Massari G; Sacchini V; Munzone E; Leonardi MC; Cattadori F; Di Micco R; Esposito E; Sgarella A; Cattaneo S; Busani M; Dessena M; Bianchi A; Cretella E; Ripoll Orts F; Mueller M; Tinterri C; Chahuan Manzur BJ; Benedetto C; Veronesi P;
JAMA Oncol; 2023 Nov; 9(11):1557-1564. PubMed ID: 37733364
[TBL] [Abstract][Full Text] [Related]
4. Regional Recurrence Rates With or Without Complete Axillary Dissection for Breast Cancer Patients with Node-Positive Disease on Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy.
Ling DC; Iarrobino NA; Champ CE; Soran A; Beriwal S
Adv Radiat Oncol; 2020; 5(2):163-170. PubMed ID: 32280815
[TBL] [Abstract][Full Text] [Related]
5. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.
Kuemmel S; Heil J; Bruzas S; Breit E; Schindowski D; Harrach H; Chiari O; Hellerhoff K; Bensmann E; Hanf V; Graßhoff ST; Deuschle P; Belke K; Polata S; Paepke S; Warm M; Meiler J; Schindlbeck C; Ruhwedel W; Beckmann U; Groh U; Dall P; Blohmer JU; Traut A; Reinisch M
JAMA Surg; 2023 Aug; 158(8):807-815. PubMed ID: 37285140
[TBL] [Abstract][Full Text] [Related]
6. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
[TBL] [Abstract][Full Text] [Related]
7. Sentinel Lymph Node Biopsy in Breast Cancer Patients With Pathological Complete Response in the Axillary Lymph Node After Neoadjuvant Chemotherapy.
Kim H; Han J; Kim SY; Lee ES; Kang HS; Lee S; Jung SY; Lee E
J Breast Cancer; 2021 Dec; 24(6):531-541. PubMed ID: 34979599
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
[TBL] [Abstract][Full Text] [Related]
11. Axillary treatment for operable primary breast cancer.
Bromham N; Schmidt-Hansen M; Astin M; Hasler E; Reed MW
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004561. PubMed ID: 28052186
[TBL] [Abstract][Full Text] [Related]
12. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
Damin AP; Zancan M; Melo MP; Biazus JV
Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
[TBL] [Abstract][Full Text] [Related]
13. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
[TBL] [Abstract][Full Text] [Related]
14. Node-Positive Patients Treated with Neoadjuvant Chemotherapy Can Be Spared Axillary Lymph Node Dissection with Wireless Non-Radioactive Localizers.
Laws A; Dillon K; Kelly BN; Kantor O; Hughes KS; Gadd MA; Smith BL; Lamb LR; Specht M
Ann Surg Oncol; 2020 Nov; 27(12):4819-4827. PubMed ID: 32740737
[TBL] [Abstract][Full Text] [Related]
15. This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients.
van Hemert AKE; van Duijnhoven FH; Vrancken Peeters MTFD
Breast; 2023 Oct; 71():89-95. PubMed ID: 37562108
[TBL] [Abstract][Full Text] [Related]
16. The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis.
Swarnkar PK; Tayeh S; Michell MJ; Mokbel K
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33810544
[TBL] [Abstract][Full Text] [Related]
17. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
[TBL] [Abstract][Full Text] [Related]
18. Oncological Safety of Skipping Axillary Lymph Node Dissection in Patients with Clinical N0, Sentinel Node-Positive Breast Cancer Undergoing Total Mastectomy.
Chun JW; Kang E; Kim HK; Lee HB; Moon HG; Lee JW; Han W
Ann Surg Oncol; 2024 May; 31(5):3168-3176. PubMed ID: 38368292
[TBL] [Abstract][Full Text] [Related]
19. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
Mariscal Martínez A; Vives Roselló I; Salazar Gómez A; Catanese A; Pérez Molina M; Solà Suarez M; Pascual Miguel I; Blay Aulina L; Ríos Gozálvez C; Julián Ibáñez JF; Rodríguez Martínez P; Martínez Román S; Margelí Vila M; Luna Tomás MA
Surg Oncol; 2021 Mar; 36():28-33. PubMed ID: 33285433
[TBL] [Abstract][Full Text] [Related]
20. Axillary lymph node dissection can be omitted in patients with limited clinically node-positive breast cancer: a National Cancer Database analysis.
Cocco D; Shah C; Wei W; Wilkerson A; Grobmyer SR; Al-Hilli Z
Br J Surg; 2022 Nov; 109(12):1293-1299. PubMed ID: 36066266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]